Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/130266
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorRodríguez-Peña, Ana B.-
dc.contributor.authorFuentes-Calvo, Isabel-
dc.contributor.authorDocherty, Neil G.-
dc.contributor.authorArévalo, Miguel-
dc.contributor.authorGrande, M. Teresa-
dc.contributor.authorEleno, Nélida-
dc.contributor.authorPérez-Barriocanal, Fernando-
dc.contributor.authorLópez-Novoa, José M.-
dc.date.accessioned2016-03-18T12:18:26Z-
dc.date.available2016-03-18T12:18:26Z-
dc.date.issued2014-
dc.identifierdoi: 10.1155/2014/124902-
dc.identifierissn: 2314-6133-
dc.identifiere-issn: 2314-6141-
dc.identifier.citationBioMed Research International: 124902 (2014)-
dc.identifier.urihttp://hdl.handle.net/10261/130266-
dc.descriptionThis is an open access article distributed under the Creative Commons Attribution License.-
dc.description.abstractTubulointerstitial fibrosis is a major feature of chronic kidney disease. Unilateral ureteral obstruction (UUO) in rodents leads to the development of renal tubulointerstitial fibrosis consistent with histopathological changes observed in advanced chronic kidney disease in humans. The purpose of this study was to assess the effect of inhibiting angiotensin II receptors or Ras activation on early renal fibrotic changes induced by UUO. Animals either received angiotensin II or underwent UUO. UUO animals received either losartan, atorvastatin, and farnesyl transferase inhibitor (FTI) L-744,832, or chaetomellic acid A (ChA). Levels of activated Ras, phospho-ERK1/2, phospho-Akt, fibronectin, and α-smooth muscle actin were subsequently quantified in renal tissue by ELISA, Western blot, and/or immunohistochemistry. Our results demonstrate that administration of angiotensin II induces activation of the small GTPase Ras/Erk/Akt signaling system, suggesting an involvement of angiotensin II in the early obstruction-induced activation of renal Ras. Furthermore, upstream inhibition of Ras signalling by blocking either angiotensin AT1 type receptor or by inhibiting Ras prenylation (atorvastatin, FTI o ChA) reduced the activation of the Ras/Erk/Akt signaling system and decreased the early fibrotic response in the obstructed kidney. This study points out that pharmacological inhibition of Ras activation may hold promise as a future strategy in the prevention of renal fibrosis.-
dc.description.sponsorshipThis study was supported by grants from Ministerio de Economía y Competitividad (Grant SAF2010-15881 and Red de Investigacion Cooperativa en Enfermedades Renales REDINREN RD12/0021/0032), Junta de Castilla y León (Grant SA 001/C05 and Excellence Group GR100), and REDINREN which is an initiative of the Instituto de Salud Carlos III of Spain supported by FEDER funds. When performing the present study, Ana B. Rodríguez-Pena was a fellow of the Fundacion Renal “Iñigo Ávarez de Toledo” and Neil G. Docherty was a fellow ofThe Marie Curie Programme, EU.-
dc.publisherHindawi Publishing Corporation-
dc.relation.isversionofPublisher's version-
dc.rightsopenAccess-
dc.titleEffect of angiotensin II and small GTPase Ras signaling pathway inhibition on early renal changes in a murine model of obstructive nephropathy-
dc.typeartículo-
dc.identifier.doi10.1155/2014/124902-
dc.relation.publisherversionhttp://dx.doi.org/10.1155/2014/124902-
dc.date.updated2016-03-18T12:18:27Z-
dc.description.versionPeer Reviewed-
dc.language.rfc3066eng-
dc.rights.licensehttp://creativecommons.org/licenses/by/3.0/-
dc.contributor.funderJunta de Castilla y León-
dc.contributor.funderFundación Renal Íñigo Álvarez de Toledo-
dc.contributor.funderFederación Española de Enfermedades Raras-
dc.contributor.funderEuropean Commission-
dc.contributor.funderMinisterio de Economía y Competitividad (España)-
dc.contributor.funderRed Española de Investigación Renal-
dc.contributor.funderInstituto de Salud Carlos III-
dc.relation.csic-
dc.identifier.funderhttp://dx.doi.org/10.13039/501100002924es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000780es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100014180es_ES
dc.identifier.pmid25101263-
dc.type.coarhttp://purl.org/coar/resource_type/c_6501es_ES
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextWith Fulltext-
item.cerifentitytypePublications-
item.openairetypeartículo-
item.grantfulltextopen-
Aparece en las colecciones: (IBMCC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
Effect of Angiotensin II.pdf3,56 MBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record

CORE Recommender

PubMed Central
Citations

7
checked on 11-abr-2024

SCOPUSTM   
Citations

13
checked on 17-abr-2024

WEB OF SCIENCETM
Citations

12
checked on 27-feb-2024

Page view(s)

271
checked on 17-abr-2024

Download(s)

221
checked on 17-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


Este item está licenciado bajo una Licencia Creative Commons Creative Commons